Omeros Co. (NASDAQ:OMER) Receives Average Rating of “Moderate Buy” from Brokerages

Shares of Omeros Co. (NASDAQ:OMER) have been assigned a consensus rating of “Moderate Buy” from the five brokerages that are covering the stock, MarketBeat Ratings reports. Two analysts have rated the stock with a hold recommendation, two have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $22.50.

Several equities analysts have recently commented on OMER shares. StockNews.com raised shares of Omeros from a “sell” rating to a “hold” rating in a research note on Tuesday, April 1st. D. Boral Capital reaffirmed a “buy” rating and set a $36.00 price target on shares of Omeros in a research report on Tuesday, April 1st. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Omeros in a research report on Tuesday, April 1st.

Omeros Stock Down 4.1 %

Omeros stock opened at $7.06 on Wednesday. The business has a 50-day simple moving average of $8.56 and a 200 day simple moving average of $7.68. Omeros has a 52 week low of $2.97 and a 52 week high of $13.60. The stock has a market cap of $409.93 million, a price-to-earnings ratio of -3.06 and a beta of 2.35.

Omeros (NASDAQ:OMER) last released its earnings results on Monday, March 31st. The biopharmaceutical company reported ($0.63) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.71) by $0.08. During the same period in the prior year, the company posted ($0.15) earnings per share. On average, research analysts anticipate that Omeros will post -3.09 earnings per share for the current year.

Institutional Investors Weigh In On Omeros

Institutional investors have recently added to or reduced their stakes in the stock. Truvestments Capital LLC increased its holdings in shares of Omeros by 116.5% in the fourth quarter. Truvestments Capital LLC now owns 3,102 shares of the biopharmaceutical company’s stock worth $31,000 after purchasing an additional 1,669 shares during the last quarter. Tower Research Capital LLC TRC boosted its stake in Omeros by 79.0% during the fourth quarter. Tower Research Capital LLC TRC now owns 4,467 shares of the biopharmaceutical company’s stock valued at $44,000 after buying an additional 1,972 shares during the last quarter. Quantbot Technologies LP purchased a new position in Omeros during the 4th quarter valued at approximately $46,000. BNP Paribas Financial Markets increased its stake in Omeros by 130.6% in the 3rd quarter. BNP Paribas Financial Markets now owns 12,388 shares of the biopharmaceutical company’s stock worth $49,000 after acquiring an additional 7,016 shares during the last quarter. Finally, Picton Mahoney Asset Management raised its holdings in shares of Omeros by 692.5% during the 4th quarter. Picton Mahoney Asset Management now owns 5,040 shares of the biopharmaceutical company’s stock worth $50,000 after acquiring an additional 4,404 shares in the last quarter. 48.79% of the stock is owned by hedge funds and other institutional investors.

About Omeros

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.